Mostrar el registro sencillo del ítem
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)
dc.creator | Wranke A., Pinheiro Borzacov L.M., Parana R., Lobato C., Hamid S., Ceausu E., Dalekos G.N., Rizzetto M., Turcanu A., Niro G.A., Lubna F., Abbas M., Ingiliz P., Buti M., Ferenci P., Vanwolleghem T., Hayden T., Dashdorj N., Motoc A., Cornberg M., Abbas Z., Yurdaydin C., Manns M.P., Wedemeyer H., Hardtke S., Serrano B., Wöbse M., Heidrich B., Muche M., Gatselis N., Zachou K., Ho E., Smedile A., Fontana R., Gish R., Obretin D., Stern R., the Hepatitis Delta International Network | en |
dc.date.accessioned | 2023-01-31T11:37:30Z | |
dc.date.available | 2023-01-31T11:37:30Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.1111/liv.13604 | |
dc.identifier.issn | 14783223 | |
dc.identifier.uri | http://hdl.handle.net/11615/80813 | |
dc.description.abstract | Background & Aims: Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with hepatitis D virus (HDV) infection and treatment approaches in different regions world-wide are poorly defined. Methods: The Hepatitis Delta International Network (HDIN) registry was established in 2011 with centres in Europe, Asia, North- and South America. Here, we report on clinical/ virological characteristics of the first 1576 patients with ongoing or past HDV infection included in the database until October 2016 and performed a retrospective outcome analysis. The primary aim was to investigate if the region of origin was associated with HDV replication and clinical outcome. Results: The majority of patients was male (n = 979, 62%) and the mean age was 36.7 years (range 1-79, with 9% of patients younger than 20 years). Most patients were HBeAg-negative (77%) and HDV-RNA positive (85%). Cirrhosis was reported in 48.7% of cases which included 13% of patients with previous or ongoing liver decompensation. Hepatocellular carcinoma (HCC) developed in 30 patients (2.5%) and 44 (3.6%) underwent liver transplantation. Regions of origin were independently associated with clinical endpoints and detectability of HDV RNA. Antiviral therapy was administered to 356 patients with different treatment uptakes in different regions. Of these, 264 patients were treated with interferon-a and 92 were treated with HBV-Nucs only. Conclusions: The HDIN registry confirms the severity of hepatitis delta but also highlights the heterogeneity of patient characteristics and clinical outcomes in different regions. There is an urgent need for novel treatment options for HDV infection. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd | en |
dc.language.iso | en | en |
dc.source | Liver International | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032289522&doi=10.1111%2fliv.13604&partnerID=40&md5=4e530b88c981a8cff29dba59066953a9 | |
dc.subject | alpha interferon | en |
dc.subject | antivirus agent | en |
dc.subject | hepatitis B(e) antigen | en |
dc.subject | antivirus agent | en |
dc.subject | hepatitis B surface antigen | en |
dc.subject | adult | en |
dc.subject | antiviral therapy | en |
dc.subject | Article | en |
dc.subject | clinical outcome | en |
dc.subject | controlled study | en |
dc.subject | delta agent hepatitis | en |
dc.subject | disease association | en |
dc.subject | disease severity | en |
dc.subject | female | en |
dc.subject | genetic heterogeneity | en |
dc.subject | Hepatitis delta virus | en |
dc.subject | human | en |
dc.subject | liver cell carcinoma | en |
dc.subject | liver cirrhosis | en |
dc.subject | liver transplantation | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | outcome assessment | en |
dc.subject | platelet count | en |
dc.subject | retrospective study | en |
dc.subject | virus replication | en |
dc.subject | adolescent | en |
dc.subject | aged | en |
dc.subject | blood | en |
dc.subject | child | en |
dc.subject | clinical trial | en |
dc.subject | complication | en |
dc.subject | cross-sectional study | en |
dc.subject | delta agent hepatitis | en |
dc.subject | genetics | en |
dc.subject | infant | en |
dc.subject | international cooperation | en |
dc.subject | liver | en |
dc.subject | liver cell carcinoma | en |
dc.subject | liver cirrhosis | en |
dc.subject | liver tumor | en |
dc.subject | middle aged | en |
dc.subject | multicenter study | en |
dc.subject | pathology | en |
dc.subject | preschool child | en |
dc.subject | register | en |
dc.subject | statistical model | en |
dc.subject | young adult | en |
dc.subject | Adolescent | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Antiviral Agents | en |
dc.subject | Carcinoma, Hepatocellular | en |
dc.subject | Child | en |
dc.subject | Child, Preschool | en |
dc.subject | Cross-Sectional Studies | en |
dc.subject | Female | en |
dc.subject | Genetic Heterogeneity | en |
dc.subject | Hepatitis B Surface Antigens | en |
dc.subject | Hepatitis D | en |
dc.subject | Hepatitis Delta Virus | en |
dc.subject | Humans | en |
dc.subject | Infant | en |
dc.subject | Internationality | en |
dc.subject | Liver | en |
dc.subject | Liver Cirrhosis | en |
dc.subject | Liver Neoplasms | en |
dc.subject | Liver Transplantation | en |
dc.subject | Logistic Models | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Registries | en |
dc.subject | Retrospective Studies | en |
dc.subject | Young Adult | en |
dc.subject | Blackwell Publishing Ltd | en |
dc.title | Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN) | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |